Search results for "Highlights"
Physician-patient discussions may decrease unnecessary self-monitoring of blood glucose levels
In a cross-sectional survey at an Ohio health system, 67% of respondents with non-insulin-controlled type 2 diabetes said they monitored their blood glucose levels because their physician had asked them to, and 50% said they would stop if given permission.
https://diabetes.acponline.org/archives/2021/09/10/2.htm
10 Sep 2021
Study finds long-term reductions in cardiovascular risk factors with SGLT-2 inhibitors
While the meta-analysis also found durable reductions in macrovascular complications and mortality with sodium-glucose cotransporter-2 (SGLT-2) inhibitors versus placebo, there were insufficient data comparing the drug class to other antihyperglycemic medications.
https://diabetes.acponline.org/archives/2021/12/10/2.htm
10 Dec 2021
Adults with diabetes more likely to report mental stress during the COVID-19 pandemic
An online survey of U.S. adults in mid-2020, most of whom were White women, found that those with diabetes were less likely to report resilience and more likely to experience depression than adults without diabetes.
https://diabetes.acponline.org/archives/2021/12/10/3.htm
10 Dec 2021
Self-monitoring of blood glucose reduced HbA1c in noninsulin-treated patients
Self-monitoring of blood glucose 8 to 11 times a week was more effective than doing so more or less frequently, according to a new meta-analysis.
https://diabetes.acponline.org/archives/2022/12/09/1.htm
9 Dec 2022
Antidepressant adherence linked to lower risk of advanced complications of diabetes
In patients with diabetes and depression in Taiwan, regular use of an antidepressant was associated with a 0.92-fold decreased risk of macrovascular complications and a 0.86-fold decreased risk of all-cause mortality compared with poor adherence.
https://diabetes.acponline.org/archives/2021/08/13/2.htm
13 Aug 2021
GLP-1 receptor agonists improved cardiovascular, kidney outcomes in type 2 diabetes
In a systematic review and meta-analysis of eight randomized controlled trials, glucagon-like peptide-1 (GLP-1) receptor agonists reduced major adverse cardiovascular events by 14%, all-cause mortality by 12%, hospital admission for heart failure by 11%, and a composite kidney outcome by 21%, with no increase in safety outcomes.
https://diabetes.acponline.org/archives/2021/09/10/3.htm
10 Sep 2021
Diets with low glycemic index or glycemic load may benefit patients with diabetes
A systematic review and meta-analysis found small improvements in established targets for glycemic control, blood lipids, adiposity, and inflammation among those with moderately controlled type 1 and type 2 disease who tried low glycemic index/load diets.
https://diabetes.acponline.org/archives/2021/08/13/3.htm
13 Aug 2021
Association between diabetes and worse COVID-19 outcomes more marked in younger adults
Among patients hospitalized with COVID-19, diabetes was a more significant risk factor for death, intensive care, or intubation in those younger than 50 years compared to older patients, a retrospective French study found.
https://diabetes.acponline.org/archives/2021/06/11/3.htm
11 Jun 2021
Newer oral diabetes meds could provide significant benefits in type 1 diabetes
A retrospective chart review found that glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors were associated with benefits including weight loss and reduced use of insulin in patients with type 1 diabetes.
https://diabetes.acponline.org/archives/2022/11/11/1.htm
11 Nov 2022
PPIs may have beneficial glycemic effects in patients with diabetes
A systematic review and meta-analysis found that proton-pump inhibitors (PPIs) improved glycemic indices in patients with diabetes and did not appear to affect risk for incident diabetes.
https://diabetes.acponline.org/archives/2021/07/09/2.htm
9 Jul 2021